Preview

Российский кардиологический журнал

Расширенный поиск

ВЫБОР ФИКСИРОВАННЫХ КОМБИНАЦИЙ АНТИГИПЕРТЕНЗИВНЫХ ПРЕПАРАТОВ С ПОЗИЦИИ ОРГАНОПРОТЕКЦИИ

https://doi.org/10.15829/1560-4071-2015-5-127-133

Полный текст:

Аннотация

В статье рассмотрены вопроса выбора комбинаций антигипертензивных препаратов с учетом их органо-протективных свойств. Подчеркивается, что поражение органов-мишеней (микроальбуминурия, повышение скорости пульсовой волны, гипертрофия миокарда левого желудочка, наличие атеросклеротических бляшек в сонных артериях, являются независимыми предикторами сердечнососудистой смертности. Рассмотрены наиболее оптимальные комбинации антигипертензивных средств при наличии поражения почек, сосудистой стенки, сердца и головного мозга. Приведены данные об органопротективных свойствах лерканидипина, эналаприла и их фиксированной комбинации.

Об авторах

О. Д. Остроумова
МГМСУ им. А.И.Евдокимова, Москва; Первый МГМУ им. И.М.Сеченова, Москва, Россия.
Россия
профессор, д.м.н., профессор кафедры факультетской терапии и профболезней, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней


И. И. Копченов
МГМСУ им. А.И.Евдокимова, Москва
Россия
к.м.н., доцент кафедры факультетской терапии и профболезней


О. В. Бондарец
МГМСУ им. А.И.Евдокимова, Москва
Россия
к.м.н., доцент кафедры факультетской терапии и профболезней


Т. Ф. Гусева
МГМСУ им. А.И.Евдокимова, Москва
Россия

к.м.н., доцент кафедры факультетской терапии и профболезней



Список литературы

1. Diagnosis and treatment of hypertension. Magazine "Systemic hypertension" 2010; 3: 5-26. Russian (Диагностика и лечение артериальной гипертензии. Журнал "Системные гипертензии" 2010; 3: 5-26).

2. Mancia G, Fagard R, Narkiewicz K, et al.2013 ESH/ESC Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Journal of Hypertension 2013, 31:1281-357.

3. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31: 883-91.

4. Sehestedt T, Jeppesen J, Hansen TW, et al. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. J Hypertens 2012; 30:1928-36.

5. Volpe M, Battistoni A, Tocci G, et al. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. J Hypertens 2012; 30:1056-64.

6. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in Anglo-Scandinavian Cardiac Outcomes Trial — Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentral randomized controlled trial. Lancet 2005;366:895-906.

7. Jamerson KA, BakrisGL, WunCC, etal. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.

8. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83.

9. Hallan S, Asberg A, Lindberg M, et al. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44: 84-93.

10. Matsushita K, Mahmodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estmated glomerular filtration rate. JAMA 2012; 307:1941-51.

11. Мое S, Drueke T, Cunningham J, et al. Definition, evaluation and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69:1945-53.

12. RedonJ, Williams B. Microalbuminuria inessential hypertension: redefining the threshold. J Hypertens 2002; 20: 353-5.

13. Jensen JS, Feldt-Rasmussen В, Strandgaard S, et al. Arterial hypertension, microalbuminuria and risk of ischemic heart disease. Hypertension 2000; 35: 898-903.

14. de Leeuw PW, Ruilope LM, Palmer CR, et al. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164:2459-64.

15. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidemiology and Prevention. Circulation 2003; 108: 2154-69.

16. Gerstein HC, Mann JR Yi Q, et al. Albuminuria and risk of cardiovascular events, death and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421 -6.

17. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 2003; 139:901-6.

18. Jager A, Kostense PJ, Ruhe HG, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the HoornStudy.ArteriosclerThrombVac Biol 1999;19:617-24.

19. Bigazzi R, Bianchi S, Baldari D, et al. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-33.

20. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Executive summary. Am J Kid Dis 2004; 43(Suppl1):S16-S33.

21. Arnlov J, Evans JC, Meigs JB, et al. Lowgrade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112: 969-75.

22. HillegeHL, FidlerV, DiercksGF, etal. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-82.

23. NinomiyaT, PerkovicV, deGalan BE, etal. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20: 1813-21.

24. Matsushita K, van der Velde M, Astor ВС, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375: 2073-81.

25. Jamerson K, Weber MA, Bakris GL, et al for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.

26. Kukes VG, Ostroumova OD, Starodubtsev AK. Calcium Antagonists: modern aspects of application in cardiology. Consilium medicum, 2006; 8 (11): 113-7. Russian (КукесВ.Г, Остроумова О. Д., Стародубцев А. К. Антагонисты кальция: современные аспекты применения в кардиологии. Consilium medicum, 2006; 8 (11): 113-7).

27. Vestra MD, Pozza G, Mosca A, et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (Diabete, Ipertensione, Albuminuria, Lercanidipina). Diab. Nutr. Metab., 2004; 17:259-66.

28. Robles NR, Ocon J, Gomez CR et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Ren Fail., 2005; 27 (1): 73-80.

29. Chazoval.E., RatovaL.G. Combination therapy of arterial hypertension. Moscow, Media Medica, 2007: 74-85. Russian (ЧазоваИ.Е., РатоваЛ.Г. Комбинированная терапия артериальной гипертонии. Москва, Медиа-Медика, 2007: 74-85).

30. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of Mild Hypertension Study (TOMHS) final results. J Am Med Assoc 1993; 270: 713-24.

31. Scholze J, Bramlage P, Trenkwalder P, Kreutz R. The efficacy and safety of fixed combinations of lercanidipine and enalapril in daily practice. Comparison of "office", ambulatory and self-measured blood pressure. Lyropecten 2012; 3:18. Russian (Эффективность и безопасность применения фиксированного сочетания леркани-дипина и эналаприла в повседневной практике. Сравнение "офисного", амбулаторного и самостоятельно измеряемого артериального давления. Лкарюпрактику 2012; 3:18).

32. Franklin SS, Larson MG, Khan SA, et al. Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation. 2001; 103(9):1245-9.

33. Assmann G, Cullen P, Evers T, et al. Importance of arterial pulse pressure as a predictor of coronary heart disease risk in PROCAM. Eur Heart J. 2005; 26(20): 2120-6.

34. Verdecchia P, Schillaci G, Borgioni C, et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. Hypertension. 1998; 32(6): 983-8.

35. Domanski MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375-80.

36. Selker HP, Beshansky J, Schmid CH. Presenting pulse pressure predicts thrombolytic therapy-related intracranial hemorrhage. Thrombolytic predictive instrument (TPI) project result. Circulation 1994; 90:1657-61.

37. Fesler P, Safar ME, du Cailar G, et al. Pulse pressure is an independent determinant of renal function decline during treatment of essential hypertension. J Hypertens 2007; 25(9):1915-20.

38. Arulkumaran N, Diwakar R, Tahir Z, et al. Pulse pressure and progression of chronic kidney disease. J Nephrol. 2010; 23(2): 189-93.

39. Ostroumova 0. D., GaleevaN.Yu. New trends in the treatment of hypertension 2013: Renaissance pulse pressure. Systemic hypertension, 2014; 1: 52-6. Russian (Остроумова О. Д., Галеева Н.Ю. Новые тенденции в лечении артериальной гипертонии 2013 года: ренессанс пульсового АД. Системные гипертензии, 2014; 1: 52-6).

40. Mackenzie I, McEnieryCM, Dhakam Z, et al. Comparison of the Effects of Antihypertension Agents on Central Blood pressure and Arterial Stiffness in Isilated Systolic Hypertension. Hypertension 2009; 54:409-13.

41. Blacher J, R Asmar, S Djane. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension, 2001; 33:1111-7.

42. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-41.

43. Vlachopoulos C, Aznaouridis K, Stefanadis С Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55: 1318-27.

44. Shevelev V I, Konorski SG. Comparison of the effects of four antihypertensive therapy on arterial wall elasticity in elderly patients with non-valvular atrial fibrillation. Cardiovascular therapy and prevention, 2013; 2 (4): 10-5. Russian (Шевелев В.И., Канорский С. Г. Сравнение влияния четырех способов антигипертензивной терапии на эластичность артериальной стенки у больных пожилого возраста с неклапанной фибрилляцией предсердий. Кардиоваскулярная терапия и профилактика, 2013; 2 (4): 10-5).

45. Heesen WR Beltman FW, Smit AJ. Effect of quinapril and triamterene/ hydrochlorthiaside on cardiac and vascular end — organ damage in isolated systolic hypertension. J of Cardiovascular Pharmacology 1998; 31 (2): 187-94.

46. Kannel WB, Gorden T, Offert D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence and mortality in the Framingham heart study. Ann Intern Med. 1969; 71:89-105.

47. Liebson PR, Grandits GA, Dianzumba S, et al. Comparison of 5 antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygienic therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 1995; 91: 698-706.

48. Mancia G, Laurent S, Agabiti-Rosei E, et al. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. JHypertens 2009; 27:2121-58.

49. Fagard RH, Celis H, Thijs L, Wouters S. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies. Hypertension 2009; 54:1084-91.

50. Bang LM, Chapman TM, Goa KL. Lercandipine — a review of its efficacy management of hypertension. Drugs, 2003; 22: 2449-72.

51. Fogari R, Mugellini A, Corradi L, et al. Efficacy of lercandipine vs losartan on left ventricular hypertrophy in hypertensive type 2 diabetic patients. J. Hypertension, 2000; 18 (Suppl.2): S65.

52. Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (PRESERVE) trial. Circulation 2001; 104:1248-54.

53. Tisaire-Sanchez J, Roma J, Camacho-Azcargorta I, et al. Assessment of cognitive function in patients with essential hypertension treated with lercanidipine. Vascular Health and Risk Management 2006: 2(4) 491-8.

54. Sabbatini M, Tomassoni D, Amenta F Influence of treatment with Ca2*-antagonists on cerebral vasculature of spontaneously hypertensive rats. Mechanisms of Ageing and Development, 2001; 122:795-809.


Для цитирования:


Остроумова О.Д., Копченов И.И., Бондарец О.В., Гусева Т.Ф. ВЫБОР ФИКСИРОВАННЫХ КОМБИНАЦИЙ АНТИГИПЕРТЕНЗИВНЫХ ПРЕПАРАТОВ С ПОЗИЦИИ ОРГАНОПРОТЕКЦИИ. Российский кардиологический журнал. 2015;(5):127-133. https://doi.org/10.15829/1560-4071-2015-5-127-133

For citation:


Ostroumova O.D., Kopchenov I.I., Bondarets O.V., Guseva T.F. FIXED ANTIHYPERTENSIVE DRUGS COMBINATION SELECTION WITH THE AIM OF ORGANS PROTECTION. Russian Journal of Cardiology. 2015;(5):127-133. (In Russ.) https://doi.org/10.15829/1560-4071-2015-5-127-133

Просмотров: 211


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1560-4071 (Print)
ISSN 2618-7620 (Online)